MRD-guided treatment-free intervals in myeloma
If a patient has had no detectable myeloma for a year or more, stop maintenance and watch, restarting only if disease reappears.
Sustained MRD negativity predicts very low relapse rates; indefinite lenalidomide adds toxicity, second cancers and cost. PERSEUS embedded dara discontinuation after sustained MRD negativity; MASTER, DRAMMATIC (SWOG S1803) and GEM2014MAIN test stopping.
Pages like this
not linked directly; found by shared links- Key paperPERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma
Shares PERSEUS, MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), Daratumumab, Lenalidomide.
- Key paperCEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), Daratumumab, Lenalidomide, Dormant cells and minimal residual disease.
- Key paperMAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), Daratumumab, Lenalidomide, Multiple myeloma.
- PairingCD38 antibody added to PI-IMiD-dex (quadruplet induction)
Shares PERSEUS, Daratumumab, Lenalidomide, Multiple myeloma.
- PersonShaji K. Kumar
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), MRD / molecular residual disease testing, Multiple myeloma.
- TrialCEPHEUS
Shares Daratumumab, Lenalidomide, Multiple myeloma.
- TermMGUS and smouldering myeloma
Shares Daratumumab, Lenalidomide, Multiple myeloma.
- TrialMajesTEC-3
Shares Daratumumab, Multiple myeloma.